Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00245050 · ClinicalTrials.gov registry record · Phase 3
Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Liposomal Doxorubicin for Cancer
A Phase 3 study, sponsored by Case Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 3
- Development phase
- 34
- Enrollment target
NCT00245050 is a Phase 3 study that has completed, run by Case Comprehensive Cancer Center. The registered enrollment target is 34 participants.
The verdict
NCT00245050, a Phase 3 study, has completed, sponsored by Case Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 34 participants
- Enrollment target
Study Summary
RATIONALE: Pyridoxine (vitamin B6) may prevent or lessen hand-foot syndrome caused by chemotherapy. It is not yet known whether pyridoxine is more effective than a placebo in preventing hand-foot syndrome. PURPOSE: This randomized clinical trial is studying pyridoxine to see how well it works compared to a placebo in preventing hand-foot syndrome in patients who are receiving liposomal doxorubicin for recurrent ovarian, fallopian tube, or peritoneal cancer, metastatic breast cancer, or advanced endometrial cancer.
Interventions
- DRUG Placebo
- DIETARY_SUPPLEMENT pyridoxine hydrochloride
- DRUG doxorubicin HCL liposome
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2004-04 |
| Est. Completion | 2011-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00245050
The ClinicalTrials.gov registry entry for NCT00245050 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Case Comprehensive Cancer Center, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00245050 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00245050 about?
NCT00245050 is a clinical study titled "Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Liposomal Doxorubicin for Cancer". RATIONALE: Pyridoxine (vitamin B6) may prevent or lessen hand-foot syndrome caused by chemotherapy. It is not yet known whether pyridoxine is more effective than a placebo in preventing hand-foot syndrome. PURPOSE: This randomized clinical trial is studying pyridoxine to see how well it works compa...
What is the current status of trial NCT00245050?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 34 participants. The study started on 2004-04. Estimated completion is 2011-09.
What interventions are being tested in trial NCT00245050?
The interventions under investigation include: Placebo (DRUG), pyridoxine hydrochloride (DIETARY_SUPPLEMENT), doxorubicin HCL liposome (DRUG).
Who is sponsoring clinical trial NCT00245050?
This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.